Anthropic’s recent establishment of a Bay Area wet lab for Claude models to run real-world biology experiments has become the main catalyst for the low but non-zero market odds on a pathogen escape. The September 2026 Reuters report highlighted this expansion into wet-lab work, prompting trader scrutiny amid broader AI safety debates, even as no confirmed biological incidents have occurred. Recent disclosures focused instead on cybersecurity evaluation mishaps involving earlier Claude versions, which Anthropic addressed through transcript reviews and safeguards. The company’s September release of Opus 5.5, positioned as its safest model with reduced breakout tendencies and automatic routing of high-risk queries, reinforces its emphasis on alignment. Competitive pressure from other labs advancing AI-biology applications and potential regulatory attention on dual-use research remain key swing factors, though the sub-10% implied probabilities through mid-2027 reflect trader confidence in existing controls and oversight.